Comparison

SARS-CoV-2 (2019-nCoV) Spike RBD-rFc Recombinant Protein European Partner

Item no. 40592-V31H-100
Manufacturer Sino Biological
Amount 100 ug
Category
Type Proteins
Specific against other
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Available
Manufacturer - Category
Protein
Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per ug protein as determined by the LAL method.
Activity
Measured by its binding ability in a functional ELISA.
Immobilized human ACE2 protein (His tag) at 2ug/mL (100uL/well) can bind 2019-nCoV Spike Protein (RBD, rabbitFc Tag) (40592-V31H), the EC50 of 2019-nCoV Spike Protein (RBD, rabbitFc Tag)is 2.0-6.0ng/mL.
Protein Construction
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with the Fc region of rabbit IgG1 at the C-terminus.
Expressed Host
HEK293 Cells
Predicted N Terminal
Arg 319
Molecule Mass
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, rabbitFc Tag) consists of 447 amino acids and predicts a molecular mass of 50.3 kDa.
Formulation
Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability and Storage
Samples are stable for up to twelve months from date of receipt at -20C to -80C
Store it under sterile conditions at -20C to -80C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
References
Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close